Cytek Biosciences Faces Revenue Decline Amid Strategic Transitions and Cost Management Efforts

Company Overview

Cytek Biosciences, Inc. (NASDAQ: CTKB) is a leading cell analysis solutions company specializing in flow cytometry and imaging technologies. The company aims to enhance biomedical research and clinical applications through advanced tools like their Full Spectrum Profiling technology.

Recent Developments

• On February 28, 2023, Cytek completed the FCI Acquisition from Luminex Corporation, enhancing its product offerings with traditional and image-based flow cytometry.
• The company is transitioning its manufacturing operations from Seattle to Singapore, expected to be completed by the end of fiscal 2025.

Income Statement Highlights

For the three months ended June 30, 2025:

• Total revenue: $45.6 million (down 2% from Q2 2024).
• Product revenue: $31.4 million (down 9% from Q2 2024).
• Service revenue: $14.2 million (up 18% from Q2 2024).
• Gross profit: $23.9 million, with a margin of 52% (down from 55% in Q2 2024).
• Operating loss: $(10.6) million (higher loss compared to $(8.5) million in Q2 2024).
• Net loss: $(5.6) million (compared to $(10.4) million in Q2 2024).
• Net loss per share: $(0.04) (compared to $(0.08) in Q2 2024).

Positive Aspects

• Service revenue growth indicates a strong need for ongoing support contracts.
• Net loss decreased compared to the same period last year, suggesting improved cost management.
• Cash and cash equivalents total approximately $75.5 million, supporting operational stability.

Negative Aspects

• Total revenue is down 2% year-over-year, primarily due to reduced product sales.
• Operating expenses increased, particularly general and administrative costs, due to ongoing patent litigation.
• Gross margin decrease indicates rising costs and lower absorption from fixed manufacturing expenses.

Financial Position Summary

• Total assets: $493.3 million, down from $499.5 million at the end of 2024.
• Total liabilities: $115.8 million, increasing from $103.8 million at year-end 2024.
• Stockholders' equity: $377.6 million, down from $395.7 million at year-end 2024.
• Cash used in operating activities: $(17,000) for the six months ended June 30, 2025.

Conclusion

Cytek is grappling with declining product revenue and rising operational costs but is making strategic transitions to enhance its market positioning. Continued focus on expanding service revenues and managing costs will be critical for future performance.